亚太地区体外诊断市场预测至 2030 年 – 区域分析 – 按产品和服务(试剂和试剂盒、仪器以及软件和服务)、技术(免疫测定/免疫化学、临床化学、分子诊断、微生物学、血液)血糖自我监测、凝血和止血、血液学、尿液分析等)、应用(传染病、糖尿病、肿瘤学、心脏病学、自身免疫性疾病、肾病学等)和最终用户(医院、实验室、家庭护理等)

Historic Data: 2020-2021   |   Base Year: 2022   |   Forecast Period: 2023-2030


No. of Pages: 121    |    Report Code: TIPRE00022120    |    Category: Life Sciences

Asia Pacific In-Vitro Diagnostics Market

亚太地区体外诊断市场预计将从2022年的191.0918亿美元增长到2030年的309.4327亿美元。预计2022年至2030年复合年增长率为6.2%。

IVD 技术与数字健康解决方案的集成推动亚太体外诊断市场

IVD 用于临床、实验室、和门诊环境,旨在帮助发现疾病,从而帮助选择适当的治疗方案。 IVD 技术与数字健康解决方案的整合正在全球范围内受到关注。数据分析、人工智能和远程监控增强了诊断测试的价值,从而实现更好的患者管理和结果。与数字健康解决方案集成的 IVD 技术可以纳入临床决策支持系统。正如世界卫生组织所认识到的,数字健康解决方案可以帮助检测疾病。人工智能健康机器人和类似的其他新兴解决方案可能会为患者护理带来机会,并解决高成本和时间要求等挑战。在基于基因组测试的诊断中,深度学习可以识别癌细胞,确定其类型,并根据特定样本的图像预测肿瘤中可能发生哪些突变。体外诊断中的人工智能和机器学习 (AI/ML) 正在彻底改变医疗设备的开发。这些现代诊断系统促进基于数字图像分析的诊断,从而改善医疗决策。智能诊断是一种可扩展性极强的 IVD 解决方案,它使用人工智能,其性能优于基于实验室的诊断,而价格仅为实验室诊断的一小部分。此外,这种类型的诊断可以通过独特的化学和生物特征检测和分析得出新兴特征。因此,IVD 与数字健康技术的整合可能会在未来几年为体外诊断市场提供利润丰厚的机会。

亚太地区体外诊断市场概览

亚太地区体外诊断市场已细分为中国、日本、印度、澳大利亚、韩国和亚太地区其他地区。中国市场的增长很大程度上归功于疾病诊断意识的不断提高。由于全国疾病流行率较高,印度在体外诊断方面占据第三大份额。上述因素对亚太地区体外诊断市场的增长具有重要影响。中国的癌症发病率和死亡率不断上升,这使得癌症成为过去十年中国的首要死因。大多数病例增加是由于人口增长(特别是老年人口激增)和社会人口变化造成的。临床试验实验室服务机构 Q2 Solutions 与广州金域诊断有限公司合作,为中国市场开发体外诊断产品和伴随诊断 (CDx)。此外,一些参与者正在投资扩大癌症生物标志物市场。 2018年8月,益普索(Ipsos) Healthcare Service Line 推出了联合实验室绘图研究和肿瘤分子诊断 (MDx) 监测器。这两项研究将在中国一、二线城市提供全面的肿瘤生物标志物测试。

亚太地区体外诊断市场收入及预测至 2030 年(百万美元)

亚太地区体外诊断市场收入及预测(百万美元)

强>

亚太地区体外诊断市场细分

亚太地区体外诊断市场分为产品和技术。服务、技术、应用程序、最终用户和国家/地区。

基于产品和服务服务,亚太体外诊断市场分为试剂和服务。套件、仪器、软件和服务。试剂&到2022年,试剂盒细分市场将占据亚太体外诊断市场的最大份额。

根据技术,亚太体外诊断市场分为免疫测定/免疫化学、临床化学、分子诊断、微生物学、血糖自我监测、凝血与治疗止血、血液学、尿液分析等。 2022年,免疫分析/免疫化学领域在亚太体外诊断市场中占据最大份额。

根据应用,亚太体外诊断市场分为传染病、糖尿病、肿瘤、心脏病学、自身免疫性疾病、肾脏病学等。到2022年,传染病领域在亚太体外诊断市场中占据最大份额。

根据最终用户,亚太体外诊断市场分为医院、实验室、家庭护理和医疗服务。其他的。到2022年,医院细分市场在亚太体外诊断市场中占据最大份额。

按国家/地区划分,亚太体外诊断市场分为中国、日本、印度、澳大利亚、南美和东南亚。韩国以及亚太其他地区。 2022 年,中国将主导亚太体外诊断市场。

雅培 (Abbott Laboratories)、碧迪公司 (Becton Dickinson and Co)、生物梅里埃 (bioMerieux SA)、伯乐 (Bio-Rad Laboratories Inc)、丹纳赫 (Danaher Corp)、罗氏 (F. Hoffmann-La Roche Ltd)、Qiagen NV 、西门子股份公司和赛默飞世尔科技公司是亚太体外诊断市场上的一些领先公司。



Asia Pacific In-Vitro Diagnostics Strategic Insights

Strategic insights for Asia Pacific In-Vitro Diagnostics involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/asia-pacific-in-vitro-diagnostics-market-strategic-framework.webp
Get more information on this report

Asia Pacific In-Vitro Diagnostics Report Scope

Report Attribute Details
Market size in 2022 US$ 19,109.18 Million
Market Size by 2030 US$ 30,943.27 Million
Global CAGR (2022 - 2030) 6.2%
Historical Data 2020-2021
Forecast period 2023-2030
Segments Covered By 产品与服务
  • 试剂与试剂盒
  • 仪器
  • 软件与服务
By 技术
  • 免疫测定/免疫化学
  • 临床化学
  • 分子诊断
  • 微生物学
  • 血糖自我监测
  • 凝血与止血
  • 血液学
  • 尿液分析
By 应用
  • 传染病
  • 糖尿病
  • 肿瘤学
  • 心脏病学
  • 自身免疫性疾病
  • 肾脏病学
By 最终用户
  • 医院
  • 实验室
  • 家庭护理
Regions and Countries Covered 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 亚太其他地区
Market leaders and key company profiles
  • Abbott Laboratories
  • Becton Dickinson and Co
  • bioMerieux SA
  • Bio-Rad Laboratories Inc
  • Danaher Corp
  • F. Hoffmann-La Roche Ltd
  • Qiagen NV
  • Siemens AG
  • Thermo Fisher Scientific Inc
  • Get more information on this report

    Asia Pacific In-Vitro Diagnostics Regional Insights

    The regional scope of Asia Pacific In-Vitro Diagnostics refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.

    geography/asia-pacific-in-vitro-diagnostics-market-geography.webp
    Get more information on this report

    The List of Companies - Asia Pacific In-Vitro Diagnostics Market

    1. Abbott Laboratories 
    2. Becton Dickinson and Co
    3. bioMerieux SA 
    4. Bio-Rad Laboratories Inc
    5. Danaher Corp 
    6. F. Hoffmann-La Roche Ltd 
    7. Qiagen NV 
    8. Siemens AG 
    9. Thermo Fisher Scientific Inc
    Frequently Asked Questions
    How big is the Asia Pacific In-Vitro Diagnostics Market?

    The Asia Pacific In-Vitro Diagnostics Market is valued at US$ 19,109.18 Million in 2022, it is projected to reach US$ 30,943.27 Million by 2030.

    What is the CAGR for Asia Pacific In-Vitro Diagnostics Market by (2022 - 2030)?

    As per our report Asia Pacific In-Vitro Diagnostics Market, the market size is valued at US$ 19,109.18 Million in 2022, projecting it to reach US$ 30,943.27 Million by 2030. This translates to a CAGR of approximately 6.2% during the forecast period.

    What segments are covered in this report?

    The Asia Pacific In-Vitro Diagnostics Market report typically cover these key segments-

  • 产品与服务 (试剂与试剂盒, 仪器, 软件与服务)
  • 技术 (免疫测定/免疫化学, 临床化学, 分子诊断, 微生物学, 血糖自我监测, 凝血与止血, 血液学, 尿液分析)
  • 应用 (传染病, 糖尿病, 肿瘤学, 心脏病学, 自身免疫性疾病, 肾脏病学)
  • What is the historic period, base year, and forecast period taken for Asia Pacific In-Vitro Diagnostics Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific In-Vitro Diagnostics Market report:

  • Historic Period : 2020-2021
  • Base Year : 2022
  • Forecast Period : 2023-2030
  • Who are the major players in Asia Pacific In-Vitro Diagnostics Market?

    The Asia Pacific In-Vitro Diagnostics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Abbott Laboratories
  • Becton Dickinson and Co
  • bioMerieux SA
  • Bio-Rad Laboratories Inc
  • Danaher Corp
  • F. Hoffmann-La Roche Ltd
  • Qiagen NV
  • Siemens AG
  • Thermo Fisher Scientific Inc
  • Who should buy this report?

    The Asia Pacific In-Vitro Diagnostics Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Asia Pacific In-Vitro Diagnostics Market value chain can benefit from the information contained in a comprehensive market report.